Supplemental Figure 1. KMO inhibition lowers PD-1 expression in PBMC CD4+ and CD8+ T cells in SIV-infected animals

A (CD4)  PD-1  HLA-DR  Ki67

Key:
- Dosing
- Upper
  - KMOi
  - Control

Lower
- Solid - KMOi
- Dashed - Control

Grey shading indicates the dosing period and the vertical line shows cART initiation. Graphs represent % CD4+ T cells (A) and % CD8+ T cells (B) positive for the indicated activation markers in PBMCs as measured by flow cytometry. KMOi-treated (black) and control animals (grey) are represented with mean+/−SE shown in upper panels and individual animals in lower panels. Differences between treatment groups in the change from baseline were assessed with linear mixed models.
Supplemental Figure 2. KMO inhibition increases naïve PBMC CD4+ T cell frequency in SIV-infected animals

A (CD4)  

Naive  

CM  

EM  

Key:  

Upper  

KMOi  

Control  

Lower  

Solid - KMOi  

Dashed - Control  

Grey shading indicates the dosing period and the vertical line shows cART initiation. Graphs represent % CD4+ T cells (A) and % CD8+ T cells (B) identified as naïve (left), central memory (center), or effector memory (right) in PBMCs as measured by flow cytometry. KMOi-treated (black) and control animals (grey) are represented with mean+/-SE shown in upper panels and individual animals in lower panels. Differences between treatment groups in the change from baseline were assessed with linear mixed models.
Supplemental Figure 3. PD-1 MFI is decreased by KMOi treatment

Grey shading indicates the dosing period and the vertical line shows cART initiation. Graphs represent the MFI of gated PD-1+ CD4+ T cells (A) and CD8+ T cells (B) in total, naive, central memory, and effector memory LN subsets as measured by flow cytometry. KMOi-treated (black) and control animals (grey) are represented with mean+/−SE in upper panels and individual animals in lower panels. Differences between treatment groups in the change from baseline were assessed with linear mixed models.
Supplemental Figure 4. IL-17 expression and SIV specific cytokine production are not enhanced by KMOi treatment

Grey shading indicates the dosing period and the vertical line shows cART initiation. In upper panels, graphs represent % IL-17+ CD4+ T cells in PBMC by flow cytometry (A), % area IL-17+ in pLN by ISH (B), and % area IL-17+ in rectal lamina propria by ISH (C). In lower panels, the two highest SIV-specific cytokine producing subsets from both CD4+ and CD8+ T cells are shown. Graphs represent % IL-2+TNFα+ CD4+ T cells (D), % TNFα+ CD4+ T cells (E), % IFNγ+TNFα+ CD8+ T cells (F), and % IFNγ+ CD8+ T cells (G) in PBMC by flow. KMOi-treated (black) and control animals (grey) are represented with mean+/SE in upper panels and individual animals in lower panels. Differences between treatment groups in the change from baseline were assessed with linear mixed models.